Why OraSure Technologies, Inc. Shares Jumped
OraSure Technologies' shares jumped by as much as 15% after the Centers for Medicare and Medicaid Services (CMS) proposed covering hepatitis-C tests for select high-risk patients. OraSure develops a rapid diagnostic test for HCV, making this potential policy change significant for the company's future revenue. If adopted, the proposal could boost OraSure's financial performance and encourage more baby boomers to get tested.
OraSure Defends Strategy Amid Activist Altai Governance Challenge
OraSure Technologies is defending its performance and governance against activist investor Altai Capital's challenge to replace two directors. The company has highlighted its growth strategy, shareholder returns matching or exceeding peers, and efforts in cost-cutting and operational restructuring. Additionally, OraSure argues that Altai undervalues its M&A pipeline and that a sale process now would jeopardize future value from FDA decisions and margin expansion.
OraSure Technologies Stock Crosses Above 200-Day Moving Average
OraSure Technologies (NASDAQ:OSUR) stock has crossed above its 200-day moving average, often considered a bullish indicator. Despite this positive technical signal, analysts currently hold a 'Reduce' rating on the stock with a consensus price target of $3.00, citing concerns about recent financial performance, including a missed earnings estimate. Investors are watching to see if the stock can maintain momentum and rebuild confidence.
OraSure Technologies (NASDAQ:OSUR) Stock Crosses Above 200-Day Moving Average - Here's What Happened
OraSure Technologies (NASDAQ:OSUR) stock recently crossed above its 200-day moving average, trading as high as $2.99. Despite this technical indicator, the company faces weak fundamentals, including a recent quarterly EPS miss and negative net margin, with analysts maintaining a "Reduce" rating and a $3.00 price target. Notably, both the CEO and CFO have recently purchased shares, indicating insider confidence despite the cautious analyst outlook.
OraSure Defends Strategy Amid Activist Altai Governance Challenge
OraSure Technologies is defending its performance and governance against activist investor Altai Capital's challenge, asserting that its shareholder returns have met or exceeded those of its peers. The company highlights its focused growth strategy, new diagnostic products, cost-cutting measures, and a debt-free balance sheet with share repurchases as evidence of its commitment to shareholder value. An analyst has a Hold rating on OSUR stock with a $3.00 price target, while TipRanks' AI Analyst Spark rates OSUR as Neutral due to past financial underperformance balanced by signs of stabilization and a promising product pipeline.
OraSure Technologies Inc (OSUR) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for OraSure Technologies Inc (OSUR), detailing its intraday performance, trading conditions for CFDs, and key statistics. It also includes related articles about other company stock forecasts, emphasizing that past performance is not indicative of future results for CFD trading.
OraSure (OSUR) director receives stock grant with tax withholding on vested shares
OraSure Technologies director Steven Kyle Boyd received a grant of 5,246 shares of common stock, valued at $3.0975 per share, as part of his routine equity compensation. These shares vested immediately and were issued in lieu of cash director fees. To cover tax liabilities related to this vesting, 1,416 shares were withheld, a non-market disposition. Following these transactions, Boyd directly holds 38,462 shares of OraSure common stock.
[8-K] ORASURE TECHNOLOGIES INC Reports Material Event
OraSure Technologies Inc. (OSUR) has filed an 8-K report detailing an investor presentation aimed at addressing its business performance and engagement with Altai Capital before its 2026 annual meeting. The company emphasizes a focused diagnostics strategy, projecting revenue growth, margin expansion, and operational cash flow breakeven in the first half of 2026, supported by new product launches and a strong balance sheet. The report also addresses a proxy contest with Altai Capital, highlighting OraSure's efforts to align with shareholders while defending its strategy and capital allocation decisions.
OSUR PE Ratio & Valuation, Is OSUR Overvalued
OraSure Technologies Inc (OSUR) is currently undervalued, with a fair price estimated between $3.45 and $5.32 compared to its current price of $3.00. While its current P/S ratio of 1.48 is considered undervalued relative to its five-year average, it is still 47.52% above the industry average, which the analysis suggests may be unsustainable given robust revenue growth of -28.53%. The article provides various valuation metrics and compares them to historical averages and industry benchmarks.
OraSure Technologies (OSUR) price target decreased by 11.11% to 4.08
This article reports a specific financial event: the price target for OraSure Technologies (OSUR) has been decreased by 11.11%, settling at $4.08. The content otherwise provides no further details regarding this adjustment or the underlying reasons.
Vanguard disaggregates holdings; OraSure (OSUR) shows 0 shares reported
Vanguard has filed an amended Schedule 13G/A for OraSure Technologies Inc. (OSUR), reporting 0 shares beneficially owned and 0% of the common stock. This change is due to an internal realignment within Vanguard, leading certain subsidiaries to report ownership separately in reliance on SEC Release No. 34-39538. The filing was signed by Ashley Grim, Head of Global Fund Administration, on March 27, 2026, and indicates a change in reporting structure rather than a market sale.
Manner Carrie Eglinton Acquires 32,300 Shares of OraSure Technologies (NASDAQ:OSUR) Stock
OraSure Technologies CEO Manner Carrie Eglinton recently acquired 32,300 shares of OSUR stock, increasing her direct ownership to over 2.19 million shares. This transaction, valued at $94,639.00, along with a prior purchase of 22,022 shares, highlights insider confidence despite the company missing its most recent quarterly EPS estimates. OraSure Technologies, a medical instruments supplier, trades around $3.08, with institutional investors holding a significant 93.5% of the stock.
OraSure (OSUR) CEO adds 32,300 shares in pre-planned 10b5-1 buy
OraSure Technologies President & CEO Carrie Eglinton-Manner purchased 32,300 shares of common stock at a weighted average price of $2.9287 per share on March 20, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following this purchase, Eglinton-Manner now directly owns 2,190,874 OraSure shares.
Insider Buying: OraSure Technologies (NASDAQ:OSUR) CFO Purchases 32,300 Shares of Stock
OraSure Technologies' CFO, Kenneth McGrath, recently purchased 32,300 shares, increasing his stake by 5.8%. This insider buying occurred despite the company reporting a quarterly loss and analysts having a "Reduce" rating with a target price close to the current stock value. The stock has shown recent upward movement and its performance metrics reflect its current market position.
OraSure Technologies (OSUR) CFO adds 32,300 shares in planned buy
OraSure Technologies CFO Kenneth J. McGrath reported an open-market purchase of 32,300 shares of common stock on March 20, 2026, at a weighted average price of $2.9288 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 28, 2025, and brings his direct holdings to 589,562 OraSure shares. The purchase indicates a planned increase in his stake rather than opportunistic timing.
Activist Altai Capital pushes for OraSure sale, board seats (update)
Activist investor Altai Capital is pressuring OraSure Technologies to explore a sale of the company and is also seeking board representation. This move indicates Altai Capital's belief that a sale or significant change in board composition could unlock greater shareholder value for OraSure.
Altai Capital Management Reduces Stake in OraSure Technologies
Altai Capital Management has reduced its stake in OraSure Technologies Inc. by selling 127,000 shares, reflecting a strategic move given that OraSure is considered significantly overvalued with declining revenue growth. Despite OraSure's moderate financial stability and strong liquidity, its poor profitability and future performance potential, as indicated by a GF Score of 63/100, suggest risks for investors. This transaction by Altai Capital may signal a reallocation of resources due to concerns over valuation and growth prospects.
[Form 4] ORASURE TECHNOLOGIES INC Insider Trading Activity
OraSure Technologies' SVP of Finance and Chief Accounting Officer, Anthony Michele Marie, reported insider trading activity involving common stock. On March 2, 2026, she received a grant of 42,982 restricted shares, vesting annually over three years. Additionally, on March 1, 2026, she acquired 14,183 shares from vested performance units and had shares withheld to cover tax liabilities, resulting in a direct holding of 185,788 shares.
Activist Altai Capital pushes for OraSure sale, board seats (update)
Activist investor Altai Capital is pressuring OraSure Technologies to explore a sale of the company and is seeking board representation. Altai Capital, which owns a significant stake in OraSure, believes the company is undervalued and that a strategic review, including a potential sale, would benefit shareholders. This move signals increasing investor pressure on OraSure's management and board.
Altai Capital Presses OraSure Board For Overhaul, Nominates Two Directors
Activist investor Altai Capital, holding a 5% stake in OraSure Technologies, is pushing for significant changes to the company's board and strategy, citing years of underperformance and concerns over governance and executive compensation. Altai has nominated two directors and is advocating for a strategic review, including a potential sale of the company. OraSure, in response, highlighted its operational progress and stated its expectation to return to revenue growth in 2026, noting that Altai has rejected all settlement proposals.
Altai Capital (OSUR) builds 5.2% OraSure stake and plans proxy fight
Altai Capital has revealed a 5.2% activist stake in OraSure Technologies (OSUR) through an amended Schedule 13D filing. The firm, led by Rishi Bajaj, beneficially owns 3,613,836 shares and plans to solicit proxies to elect Rishi Bajaj and John Bertrand to OraSure's board at the upcoming annual meeting, outlining its "case for change" in an open letter. This move signals a governance campaign aimed at influencing the company's direction.
OraSure Technologies CFO Buys Over $66,000 in Company Stock
OraSure Technologies CFO Kenneth Mcgrath recently purchased 22,021 shares of the company's stock for over $66,000, increasing his ownership stake by 4.11%. This insider purchase is viewed as a positive signal, indicating Mcgrath's confidence in the medical diagnostics company's future prospects and suggesting the stock may be undervalued despite a recent net loss.
Altai Capital (OSUR) Seeks Board Seats, Urges Strategic Review and Sale
Altai Capital, a major shareholder of OraSure Technologies (OSUR) with approximately 5% ownership, has nominated two directors, Rishi Bajaj and John Bertrand, to the company's board. Altai Capital criticizes OraSure's chronic underperformance, misaligned CEO compensation, and poor capital allocation decisions, including significant investments in Sapphiros and Sherlock Biosciences. The firm is pushing for a strategic review of the business, including evaluating a potential sale, and aims to secure board seats for its nominees to drive shareholder value.
OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
OraSure Technologies, Inc. responded to Altai Capital's letter, emphasizing its significant operational progress and value creation initiatives. The company highlighted its momentum on a transformation strategy with upcoming regulatory and commercial milestones in 2026, while stating that Altai Capital's founder is seeking board representation to force an ill-timed sale. OraSure detailed its growth strategy, innovation roadmap, cost reduction efforts, balanced capital allocation, and a refreshed board, asserting its commitment to long-term shareholder value.
OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
OraSure Technologies, Inc. has responded to Altai Capital's letter, emphasizing its commitment to driving shareholder value through strategic execution and operational improvements. The company highlights its progress in 2025 and anticipated revenue growth in 2026, driven by new product launches and cost-reduction initiatives, while rejecting Altai's demands for Board representation and an ill-timed sale. OraSure states that Altai's founder is seeking to derail the company's strategy and has refused multiple settlement offers.
Activist Altai Capital pushes for OraSure sale, board seats (OSUR:NASDAQ)
Activist investor Altai Capital is urging OraSure Technologies (OSUR) to explore a potential sale, believing it could significantly increase the medical device maker's share price. Altai Capital estimates OraSure's value could range from $4.54 to $6.60 per share in a sale, representing a substantial premium to its current price. The activist investor is also pushing for board seats to help facilitate this strategic direction.
Altai Capital pushes for board seats at OraSure Technologies
Altai Capital Management, which owns approximately 5% of OraSure Technologies Inc. (NASDAQ:OSUR), has called for two director nominees, Rishi Bajaj and John Bertrand, to be appointed to OraSure's board. The investment firm criticized OraSure's underperformance, including a 60% loss for shareholders since 2023, negative EBITDA, and misaligned executive compensation, advocating for a strategic review that includes a potential sale of the entire business. OraSure recently reported fourth-quarter 2025 revenue of $26.8 million, missing forecasts, and continues to face financial hurdles despite expected growth from upcoming product launches.
Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
Altai Capital Management, a significant shareholder of OraSure Technologies (NASDAQ: OSUR), has sent a letter to the OraSure Board outlining five reasons why change is crucial due to the company's chronic underperformance, misaligned executive compensation, and lack of independent director ownership. Altai is pushing for a fair settlement that includes the appointment of their highly-qualified nominees, Rishi Bajaj and John Bertrand, to the Board to advocate for a strategic review and shareholder interests. They argue that these nominees have a proven track record of driving shareholder value, unlike the current board and management.
Altai Capital Urges OraSure Technologies Board to Address Operational Inefficiencies and Leadership Concerns
Altai Capital Management has sent a letter to OraSure Technologies' board, advocating for significant changes due to the company's continuous underperformance. The investment firm, a major stakeholder, proposes a five-pillar plan to enhance operational efficiency, optimize capital allocation, improve governance, address leadership issues, and refine strategic direction. Altai Capital aims to unlock shareholder value and ensure the company's long-term success through these urgent improvements.
Altai Capital angles for OraSure board seats and a sale
Altai Capital Management is pushing OraSure Technologies to consider selling its entire business and revisit its M&A strategy, citing years of declining stock prices and slowing diagnostic sales post-COVID. The hedge fund, which has increased its stake in OraSure to 5.2%, has proposed two candidates, including its founder Rishi Bajaj, for the board of directors. Altai criticizes OraSure's recent investments and believes the company's value could be significantly higher in a sale than as a standalone entity.
Insider Buying: OraSure Technologies (NASDAQ:OSUR) CEO Purchases 22,022 Shares of Stock
OraSure Technologies (NASDAQ:OSUR) CEO Manner Carrie Eglinton recently purchased 22,022 shares of the company's stock for $66,066, increasing her direct ownership by 1.03%. The stock is currently trading around $3.13, with a 52-week range of $2.08 to $4.22. Analysts maintain a "Reduce" rating with an average price target of $3.00, and institutional investors hold a significant portion of the shares.
OraSure Technologies (NASDAQ:OSUR) CFO Kenneth Mcgrath Purchases 22,021 Shares of Stock
OraSure Technologies CFO Kenneth Mcgrath recently purchased 22,021 shares of OSUR stock for $66,063, increasing his total holdings to 557,262 shares. This transaction boosts his stake by 4.11%, valuing his position at approximately $1.67 million. The stock is currently trading at $3.13, with analysts giving it a "Reduce" consensus rating and an average price target of $3.00.
Altai Capital Management L.P. Has $12.03 Million Stake in OraSure Technologies, Inc. $OSUR
Altai Capital Management L.P. significantly increased its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) during the 3rd quarter, now owning 3,748,836 shares worth approximately $12.03 million and constituting 23.6% of its investment portfolio. This makes OraSure Technologies Altai's second-largest position. Despite strong institutional ownership, analysts have a "Reduce" consensus rating with a target price of $3.00, and the stock recently traded at $2.97.
OraSure Technologies (NASDAQ:OSUR) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened
OraSure Technologies (NASDAQ:OSUR) recently crossed above its 200-day moving average, trading as high as $3.15 before settling at $2.97. Despite this, the stock carries a "Reduce" consensus rating with a $3.00 target price, and has negative fundamentals including recent earnings per share that missed estimates and a negative net margin. Institutional investors have made various adjustments to their holdings in the company.
Former VA head departs OraSure board
Dr. David Shulkin, former U.S. Secretary of Veterans Affairs, has resigned from the board of directors of OraSure Technologies (OTI), effective March 2. His departure was not due to any disputes and leaves six members on the board. This comes after Altai Capital Management, a hedge fund owning over 5% of OraSure's stock, nominated two of its own representatives to the board, including its president, Rishi Bajaj, who has criticized OraSure's leadership.
OraSure Technologies (Nasdaq:OSUR) - Stock Analysis
This Simply Wall St report provides a detailed stock analysis of OraSure Technologies (OSUR), highlighting its current market capitalization at US$205.3m and a share price of US$2.97. The analysis covers valuation, growth prospects, past performance, financial health, dividends, management, and ownership, indicating the stock is undervalued based on analyst consensus. The report also lists recent news, key performance indicators, and competitive landscape.
Orasure Technologies, Inc. Announces Resignation of David J. Shulkin as Director and Compensation Committee Member of the Board, Effective March 2, 2026
OraSure Technologies, Inc. announced that David J. Shulkin, M.D., has resigned from his position as a director and member of the Compensation Committee of the Board, effective March 2, 2026. The company made this announcement on February 28, 2026, and the news was published on March 5, 2026, at 4:15 pm EST.
OraSure Technologies (NASDAQ:OSUR) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened
OraSure Technologies (NASDAQ:OSUR) saw its stock price cross above its 200-day moving average of $2.79 on Thursday, trading as high as $3.04. Despite this, analyst sentiment remains negative, with a consensus rating of "Reduce" and a price target of $3.00, following the company missing its most recent quarterly EPS estimates. Institutional investors have been adjusting their positions, with hedge funds owning 93.50% of the company's stock.
OraSure Technologies Announces Resignation of Board Member Shulkin
OraSure Technologies announced the resignation of board member David J. Shulkin, M.D., effective March 2, 2026. The company confirmed his departure was not due to any disagreement and thanked him for his service. OraSure Technologies (OSUR) currently holds a Hold rating from analysts with a $3.00 price target, and TipRanks’ AI Analyst, Spark, also rates OSUR as Neutral due to financial performance concerns despite some stabilization signals.
OraSure (OSUR) CFO granted stock awards and withholds shares for taxes
OraSure Technologies' CFO, Kenneth J. McGrath, received equity awards totaling 115,162 shares (88,348 and 26,814 shares) at $0.00 per share on March 1 and March 2, 2026, through grants and settlement of vested performance units and restricted stock. Simultaneously, 28,384 shares (7,639 and 20,745 shares) were withheld at $3.0425 per share to cover tax liabilities, not through open-market sales. After these transactions, McGrath directly owned 535,241 shares, with new restricted stock set to vest in three equal annual installments starting March 2, 2027.
OraSure (OSUR) CEO gets major stock awards, shares withheld for taxes
OraSure Technologies' President & CEO, Carrie Eglinton Manner, was granted 355,464 restricted shares as equity compensation, vesting in three annual installments starting March 2, 2027. She also acquired 129,032 shares from vested performance units. Additionally, 56,116 and 122,655 shares were withheld at $3.0425 per share to cover tax liabilities related to these vesting events, bringing her direct ownership to 2,136,552 common shares.
OraSure Technologies, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:OSUR) 2026-03-03
OraSure Technologies, Inc. (OSUR) has published its Q4 2025 earnings call presentation. The company reported an EPS miss of $0.04 with -$0.19 and revenue of $26.76 million, a 28.53% year-over-year decrease, yet it still beat estimates by $319.64K. This presentation provides details related to their financial performance.
OraSure Technologies, Inc. (NASDAQ:OSUR) Q4 2025 Earnings Call Transcript
OraSure Technologies (NASDAQ:OSUR) reported fourth-quarter 2025 financial results, with total revenue of $26.8 million, slightly above guidance, but missed EPS expectations at $-0.19. The company highlighted stabilizing order trends in its International Diagnostics business, expanded presence in Canada with its HIV Self-Test, and the successful integration of BiMedomics. OraSure also anticipates growth in its Sample Management Solutions and is progressing with two key product launches mid-year: a rapid molecular self-test for chlamydia and gonorrhea (CT/NG) and a Colli-Pee at-home urine collection device for STIs, both submitted to the FDA in December.
OraSure Technologies (OSUR) Loss Worsens To US$0.27 EPS And Tests Margin Recovery Narrative
OraSure Technologies (OSUR) reported a Q4 FY 2025 basic EPS loss of US$0.27 on revenues of US$26.8 million, indicating a worsening financial performance. The company's quarterly revenues have declined significantly through FY 2025, and net losses have widened, leading to concerns about the business's ability to support its cost structure. Despite a seemingly low P/S ratio compared to the industry, ongoing losses and modest growth forecasts raise questions about its valuation.
OraSure Technologies (OSUR) Loss Worsens To US$0.27 EPS And Tests Margin Recovery Narrative
OraSure Technologies (OSUR) reported a worsening loss in Q4 FY 2025, with a basic EPS loss of US$0.27 and revenue of US$26.8 million, raising concerns about margin recovery. The company's trailing twelve-month revenue has shrunk, and losses have deepened, leading to skepticism despite a seemingly low P/S ratio compared to the industry. The article highlights the ongoing debate between bullish investors, who see value in the low P/S, and bearish investors, who focus on the persistent unprofitability and shrinking revenue.
OraSure Highlights 2025 Results and 2026 Growth Outlook
OraSure Technologies reported fourth-quarter 2025 net revenue of $26.8 million, noting a 29% year-over-year decrease and a total 38% decline for 2025 due to reduced COVID-19 and other testing. Despite these challenges, management expects a return to growth in 2026, supported by improved funding, stronger gross margins, a solid balance sheet, a share repurchase program, and upcoming U.S. product launches. An analyst rating for OSUR stock is currently a Hold with a $3.00 price target.
OraSure Technologies Inc reports results for the quarter ended September 30 - Earnings Summary
OraSure Technologies Inc has reported its earnings results for the quarter that ended on September 30. This brief summary from Refinitiv highlights the key financial outcomes for the company during this period.
OraSure: Fourth Quarter Financial Results Overview
OraSure Technologies reported a net loss of $19.3 million, or 27 cents per share, for the fourth quarter, with an adjusted loss of 19 cents per share. The company generated $26.8 million in revenue for the quarter and a total loss of $68.7 million, or 94 cents per share, with $115 million in annual revenue. For the first quarter, OraSure anticipates revenue between $26 million and $29 million.
OraSure Announces Fourth Quarter 2025 Financial Results
OraSure Technologies, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported total net revenues of $26.8 million for Q4 2025, a 29% decrease year-over-year, and a net loss of $19.3 million. Despite a challenging funding environment in 2025, OraSure is optimistic about returning to growth in 2026 with anticipated U.S. regulatory clearances for new rapid molecular self-tests and collection devices, and continues to execute its share repurchase program.
OraSure Announces Fourth Quarter 2025 Financial Results
OraSure Technologies, Inc. (NASDAQ: OSUR) announced its financial results for the fourth quarter of 2025, reporting total net revenues of $26.8 million, a 29% decrease from the previous year. Despite a challenging funding environment in 2025, the company's results were consistent with expectations, and they anticipate a return to growth in 2026 driven by planned regulatory clearances and product launches. OraSure remains confident in its strategy to expand access to diagnostics and continues to execute its $40 million share repurchase program.
